Latest news with #MarcLemieux
Globe and Mail
5 days ago
- Business
- Globe and Mail
KDA GROUP ANNOUNCES CLOSING OF PRIVATE PLACEMENT
THETFORD MINES, QC , May 29, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) (" KDA" or the " Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the closing of a private placement with accredited investors totaling 8,800,000 units (the " Units") at a price of $0.25 per Unit for total gross proceeds of $2,200,000 (the " Private Placement"). Each Unit consists of one Class A Share of KDA (" Common share") and one Common share purchase warrant (a " Warrant"). Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of $0.35 per Common share for a period of 24 months ending May 29, 2027. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one-day hold period expiring on September 30, 2025 in accordance with applicable securities regulations. KDA will use the Private Placement proceeds for its working capital and general corporate purposes. No finder's fee nor commission are payable in connection with the Private Placement. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange. Marc Lemieux , an officer and director of the Corporation, purchased 80,000 Units for a total consideration of $20,000 . Marc Lemieux is hereinafter referred to as the "Insider". The Insider is considered "related party" and "insider" of the Corporation for the purposes of applicable securities laws and stock exchange rules. The subscription and issuance of Units by the Insider constitutes a related party transaction but is exempt from the formal valuation and minority approval requirements of Regulation 61-101 respecting Protection of Minority Security Holders in Special Transactions as neither the fair market value of the Common shares and Warrants issued to the Insider, nor the consideration paid by such Insider, exceeds 25% of the Corporation's market capitalization. ABOUT KDA GROUP KDA Group is a leader in technological innovations and specialized software solutions (SaaS – Software as a service) for the healthcare professionals' market. KDA is a corporation that offers quality products and has respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare's digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at and on SEDAR+ at CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption , goal , guidance , objective , outlook , strategy , target, and other similar expressions, or future or conditional verbs such as aim , anticipate , believe , predict , could , expect , intend , may , plan , seek , should , strive, and will . By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Cision Canada
5 days ago
- Business
- Cision Canada
KDA GROUP ANNOUNCES CLOSING OF PRIVATE PLACEMENT Français
THETFORD MINES, QC, May 29, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) (" KDA" or the " Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the closing of a private placement with accredited investors totaling 8,800,000 units (the " Units") at a price of $0.25 per Unit for total gross proceeds of $2,200,000 (the " Private Placement"). Each Unit consists of one Class A Share of KDA (" Common share") and one Common share purchase warrant (a " Warrant"). Each Warrant entitles the holder to purchase one additional Common share of the Corporation at an exercise price of $0.35 per Common share for a period of 24 months ending May 29, 2027. All securities issued pursuant to the Private Placement are subject to a mandatory four-month and one-day hold period expiring on September 30, 2025 in accordance with applicable securities regulations. KDA will use the Private Placement proceeds for its working capital and general corporate purposes. No finder's fee nor commission are payable in connection with the Private Placement. The Private Placement was carried out pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSX Venture Exchange. Marc Lemieux, an officer and director of the Corporation, purchased 80,000 Units for a total consideration of $20,000. Marc Lemieux is hereinafter referred to as the "Insider". The Insider is considered "related party" and "insider" of the Corporation for the purposes of applicable securities laws and stock exchange rules. The subscription and issuance of Units by the Insider constitutes a related party transaction but is exempt from the formal valuation and minority approval requirements of Regulation 61-101 respecting Protection of Minority Security Holders in Special Transactions as neither the fair market value of the Common shares and Warrants issued to the Insider, nor the consideration paid by such Insider, exceeds 25% of the Corporation's market capitalization. ABOUT KDA GROUP KDA Group is a leader in technological innovations and specialized software solutions (SaaS – Software as a service) for the healthcare professionals' market. KDA is a corporation that offers quality products and has respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare's digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at and on SEDAR+ at This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Yahoo
21-05-2025
- Business
- Yahoo
KDA GROUP RECEIVES DSQ CERTIFICATION FOR ADHERIZE+ PLATFORM -- MEDHERIZE MODULE ENTERS CLINICAL DEPLOYMENT PHASE
THETFORD MINES, QC, May 21, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce that its Adherize+ platform, designed to optimize patient follow-up and care coordination, has officially received certification from Dossier Santé Québec ("DSQ"). This authorization marks a major step toward full production deployment. At the core of Adherize+ is Medherize, a high-impact specialized module developed to support interdisciplinary follow-up for patients undergoing targeted cancer therapies. Leveraging structured, real-time data exchange through granular integration, a first in Quebec, Medherize brings significant value to healthcare operations and outcomes, positioning it as a key strategic asset within the Adherize+ ecosystem for the entire Quebec population. With this certification secured, the pilot project at Hôpital Saint-Sacrement in Quebec City is set to begin, marking the start of a phased rollout to other healthcare institutions across the province. "Achieving DSQ certification demonstrates the strength and maturity of our technology. Medherize allows us to deliver a highly effective solution to support specialized treatment journeys. And this is just the beginning, KDA is already working to expand Medherize to other specialty drugs that require complex follow-up and are dispensed through community pharmacies," said Yves Marmet, President and Chief Technology Officer of Groupe Technologique KDA. As more specialty therapies are delivered orally and managed outside of hospitals by community pharmacies, the need for robust digital tools like Medherize are becoming essential for physicians, pharmacists, and nursing staff. These high-cost treatments are often associated with significant adverse effects and adherence challenges. Ensuring appropriate monitoring can directly impact patient survival and reduce systemic risks. Medherize is designed to meet this growing need, improving continuity of care for patients whose lives depend on strict therapeutic management. "This milestone is the result of tremendous work from our team and the support of our clinical partners. With this foundation in place, we're accelerating our mission to provide high-value, connected tools for healthcare professionals and patients alike, for the entire international market," added Marc Lemieux, Chief Executive Officer and Chairman of the Board of KDA. KDA reaffirms its leadership in digital health innovation in Quebec and positions itself for sustained growth as Medherize transitions from certification to clinical integration. ABOUT KDA GROUP KDA Group is a leader in technological innovations and specialized software solutions (SaaS – Software as a service) for the healthcare professionals' market. KDA is a corporation that offers quality products and has respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare's digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at and on SEDAR+ at CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. SOURCE KDA Group Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
21-05-2025
- Business
- Cision Canada
KDA GROUP RECEIVES DSQ CERTIFICATION FOR ADHERIZE+ PLATFORM -- MEDHERIZE MODULE ENTERS CLINICAL DEPLOYMENT PHASE Français
THETFORD MINES, QC, May 21, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) (" KDA" or the " Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce that its Adherize+ platform, designed to optimize patient follow-up and care coordination, has officially received certification from Dossier Santé Québec (" DSQ"). This authorization marks a major step toward full production deployment. At the core of Adherize+ is Medherize, a high-impact specialized module developed to support interdisciplinary follow-up for patients undergoing targeted cancer therapies. Leveraging structured, real-time data exchange through granular integration, a first in Quebec, Medherize brings significant value to healthcare operations and outcomes, positioning it as a key strategic asset within the Adherize+ ecosystem for the entire Quebec population. With this certification secured, the pilot project at Hôpital Saint-Sacrement in Quebec City is set to begin, marking the start of a phased rollout to other healthcare institutions across the province. "Achieving DSQ certification demonstrates the strength and maturity of our technology. Medherize allows us to deliver a highly effective solution to support specialized treatment journeys. And this is just the beginning, KDA is already working to expand Medherize to other specialty drugs that require complex follow-up and are dispensed through community pharmacies," said Yves Marmet, President and Chief Technology Officer of Groupe Technologique KDA. As more specialty therapies are delivered orally and managed outside of hospitals by community pharmacies, the need for robust digital tools like Medherize are becoming essential for physicians, pharmacists, and nursing staff. These high-cost treatments are often associated with significant adverse effects and adherence challenges. Ensuring appropriate monitoring can directly impact patient survival and reduce systemic risks. Medherize is designed to meet this growing need, improving continuity of care for patients whose lives depend on strict therapeutic management. "This milestone is the result of tremendous work from our team and the support of our clinical partners. With this foundation in place, we're accelerating our mission to provide high-value, connected tools for healthcare professionals and patients alike, for the entire international market," added Marc Lemieux, Chief Executive Officer and Chairman of the Board of KDA. KDA reaffirms its leadership in digital health innovation in Quebec and positions itself for sustained growth as Medherize transitions from certification to clinical integration. ABOUT KDA GROUP KDA Group is a leader in technological innovations and specialized software solutions (SaaS – Software as a service) for the healthcare professionals' market. KDA is a corporation that offers quality products and has respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare's digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at and on SEDAR+ at This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Globe and Mail
15-04-2025
- Business
- Globe and Mail
KDA GROUP REACHES FINAL CERTIFICATION PHASE FOR MEDHERIZE WITH DSQ
THETFORD MINES, QC , April 15, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) (" KDA" or the " Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce that it has reached the final phase in the certification process for its Medherize platform's integration with the Dossier Santé Québec (" DSQ"). Following the successful completion of the initial certification phase announced on December 3, 2024 , all three required development phases for the module have now been completed. On April 7, 2025 , the Direction des produits de prestations de services du DSQ, through its Integration and Certification Support Team, confirmed that the final self-assessment phase was successfully passed. The final audit is scheduled for April 22–24, 2025, marking the last technical validation before full integration. The initial deployment of Medherize is planned for May 5, 2025 , at the St-Sacrement Hospital Center in Québec City, followed by a progressive rollout across other healthcare institutions in the province. KDA is now the first technology provider in Québec to successfully certify for DSQ integration using the granular data mode —a major advancement in the transmission of clinical information. Unlike laboratory results delivered in PDF format, which are often static and difficult to process, the granular mode enables structured, interoperable, and seamlessly integrable data within clinical systems. This model provides substantial gains in efficiency, safety, quality of care, as well as reductions in delays and human error. "This achievement confirms our role as a pioneer in digital health. With the certification of the granular mode, the Medherize platform can now deliver an advanced and innovative technological experience, powered by structured, automated, and real-time clinical data. It's a paradigm shift that positions Québec at the forefront of connected medicine," said Yves Marmet , President and Chief Technology Officer of Groupe Technologique KDA. "Innovation has always been at the heart of our mission, but this milestone marks a turning point. It demonstrates not only our ability to deliver real-world solutions, but also our deep commitment to the long-term transformation of the healthcare system. I wish to recognize the outstanding work of our team," added Marc Lemieux , Chief Executive Officer and Chairman of the Board of KDA. KDA extends its sincere congratulations to its development team for successfully completing this crucial phase, reinforcing the Corporation's position as a leading player in digital health innovation in Québec and beyond. ABOUT KDA GROUP KDA Group is a leader in technological innovations and specialized software solutions (SaaS – Software as a service) for the healthcare professionals' market. KDA is a corporation that offers quality products and has respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare's digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at and on SEDAR+ at This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption , goal , guidance , objective , outlook , strategy , target, and other similar expressions, or future or conditional verbs such as aim , anticipate , believe , predict , could , expect , intend , may , plan , seek , should , strive, and will . By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
